

CytoDyn Inc.

16:00 21 Feb 2020

NA Proactive news snapshot: CytoDyn, Mandalay Resources, CleanSpark, Duos Technologies, Quantum Computing - UPDATE

Duos Technologies Group Inc (NASDAQ:DUOT) has raised a further \$1.06 million in net proceeds after an over-allotment was exercised on the previously announced public offering, it said Friday. On February 13, the analytical technology solutions group, said it had offered 1.3 million shares at \$6 a share in the \$8 million raise. Today, the group said the underwriters had partially exercised and closed on their over-allotment option and bought an additional 192,188 shares at \$6 each. Duos intends to use the net proceeds for research and development activities, sales and marketing, and for general working capital

Quantum Computing Inc (OTCMKTS:QUBT) is adding key medical expertise to its technical advisory board. The Leesburg, Virginia-based technology firm said Dr Michael Liebman is joining its advisory board to add a "unique perspective" that will allow the company to apply its techniques to the pharmaceutical and healthcare sectors. Liebman's research focuses on computational models of disease progression that stress risk detection, disease processes and clinical pathway modeling, and disease stratification from the clinical perspective.

CytoDyn Inc (OTCMKTS:CYDY) announced Friday it will begin its Phase 2 clinical trial of leronlimab (PRO 140) for the treatment of about 22 different solid tumor cancers. In a statement, the company said it is launching the second study after receiving Institutional Review Board (IRB) approval to target melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other cancers.

Mandalay Resources Corp (TSE:MND) (OTCMKTS:MNDJF) told investors that full-year 2019 was 'challenging' but the fourth quarter to end December saw significant improvement as grades improved and production was boosted. The metals miner operates mines in Sweden (Björkdal) and Australia (Costerfield) and produces gold, silver and antimony.


CleanSpark Inc (NASDAQ:CLSK) put out a statement after the bell Thursday, informing investors that it had no material information as to why its share price moved more than usual during trading. The energy software and technology company, which uplisted to the Nasdaq in January, saw its second-highest trading volume of the month, and shares dipped 11%, but the company insists there is no clear reason for a decline.

Agile Therapeutics Inc (NASDAQ:AGRX), which is preparing to commercialize its lead product Twirla, announced Friday the pricing of its underwritten public offering that's expected to raise about \$45 million. The Princeton, New Jersey-based women's health company is offering 15 million shares of its common stock at a price of \$3 per share -- which closed at \$3.58 on Thursday. In addition, Agile Therapeutics has granted the underwriters a 30-day option to purchase up to 2.25 million additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The FDA recently approved Twirla, a low-dose prescription contraceptive delivered

Price: 2.83

Market Cap: \$1.37 billion

1 Year Share Price Graph



Share Information

Code: CYDY

Listing: OTCQB

52 week	High	Low
	3.84	0.261

Sector: Pharma & Biotech

Website: www.cytodyn.com

Company Synopsis:

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man.

action@proactiveinvestors.com

through the skin.

Antibe Therapeutics Inc. (CVE:ATE) (OTCMKTS:ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50 company for the second consecutive year, in recognition of its performance on the TSX Venture Exchange. Dan Legault, Antibe's CEO commented: "It's exciting to be recognized as a TSX Venture top performer for the second year in a row. We believe this award reflects a growing awareness of the best-in-class potential of our drug pipeline," He added: "We hope to continue this success for our shareholders, as we complete our lead drug's final Phase 2 trial, expand partnering activities and evolve into a Phase 3 company. We look forward to reaching a growing audience of institutional and retail investors in the coming year."

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, announced that it will report its fourth-quarter and full-year 2019 financial and operating results after the close of US financial markets on Thursday, February 27, 2020. In addition, the group said its management will host a conference call to provide an update on corporate activities and discuss the quarterly and full-year financial results.

Thunderbird Entertainment Group Inc. (CVE:TBRD) (OTCMKTS:THBRF), a global, multiplatform entertainment company with offices in Los Angeles, Vancouver, Ottawa and Toronto, said it will hold a conference call and webcast to share the Company's second quarter 2020 financial results on Monday, March 2, 2020 at 6am PST/9am EST.

Metalla Royalty & Streaming Ltd. (CVE:MTA) (NYSEAMERICAN:MTA) said its board of directors has approved and declared a monthly cash dividend payment of CAD \$0.004 per share for March, April, and May 2020, on its common shares, subject to any applicable tax withholding obligations).

Tocvan Ventures Corp. (CSE:TOC) (CNSX:TOC.CN) said it has granted an aggregate of 175,000 stock options to directors, officers and consultants of the corporation under its stock option plan, at an exercise price of \$0.22 per common share and expiring five years from the date of grant.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand

dollars

(\$25,000).